Literature DB >> 20029210

Caspase-4 activation in association with decreased adenosine deaminase activity may be a factor for gastric ulcer.

Takahiro Yaguchi1, Masaru Saito, Yoshiyuki Yasuda, Tomoyuki Nishizaki.   

Abstract

BACKGROUND/AIMS: Adenosine deaminase (ADA)-deficient disease, a severe combined immunodeficiency, is most commonly associated with gastrointestinal disorders such as ulcer. The present study investigated the role of ADA in the pathogenesis of gastric ulcer.
METHODS: ADA activity was measured in a variety of organs and tissues from rats and in human gastric biopsy samples from patients who underwent gastrofiberscope. An MTT assay and TUNEL staining were carried out, and activity of caspase-3 and -4 was enzymatically measured in MKN45 human gastric cancer cells. In the Western blot analysis, caspase-4 activation was identified in gastric biopsy samples.
RESULTS: In rat organs and tissues, the epithelium of the gastrointestine exhibited higher ADA activity. The ADA inhibitor EHNA reduced cell viability, increased TUNEL-positive cells, and activated caspase-3 and -4 in MKN45 cells. For gastric biopsy samples, much lower ADA activity was found in gastric ulcer tissues, with a tendency of caspase-4 activation.
CONCLUSION: A decline in ADA activity and the ensuing increase in intracellular adenosine concentrations for the stomach could induce gastric epithelial cell apoptosis by activating caspase-4 and the effector caspase-3. This may represent a fresh pathogenetical pathway for gastric ulcer relevant to ADA activity and caspase-4 activation. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20029210     DOI: 10.1159/000252771

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  1 in total

1.  Prognostic significance of mRNA expression of CASPs in gastric cancer.

Authors:  Zixiang Wang; Fubiao Ni; Fangyi Yu; Zhonghui Cui; Xiandong Zhu; Jicai Chen
Journal:  Oncol Lett       Date:  2019-09-05       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.